Safety & Infection Control
Comprehensive safety protocols for hirudotherapy practice
Last Updated: March 1, 2026Reviewed by: Andrei Dokukin, MDRegulatory Status: FDA-Cleared (Tier 1)
FDA-Cleared Indication
Safety and infection control protocols are essential components of FDA-compliant medicinal leech therapy practice.
Patient safety in hirudotherapy centers on three pillars: infection prevention (Aeromonas prophylaxis), bleeding management, and contraindication screening. This page provides evidence-based protocols for each.
Aeromonas Infection Prevention
Critical Safety Information
Aeromonas hydrophila accounts for 88% of all infectious complications following leech therapy. Infection rates: 7-20% without prophylaxis, <5% with prophylaxis, and 0% in prospective series with standardized protocols (Nguyen 2012, n=39).
Antibiotic Prophylaxis Protocol
| Component | Recommendation |
|---|---|
| First-line | Ciprofloxacin 500 mg BID + TMP-SMX DS 160/800 mg BID |
| Timing | Begin BEFORE first leech application |
| Duration | Through treatment + 3-5 days after final application |
| Avoid | First-gen cephalosporins (intrinsic Aeromonas resistance) |
| Resistance concern | Ciprofloxacin resistance: 43% environmental isolates; culture-directed therapy if infection develops |
| Batch surveillance | Culture 1 leech per 50 on delivery and every 30 days in storage |
Bleeding Management
Blood Loss Parameters
- Per leech: 5-15 mL feeding + 10-50 mL post-detachment = 15-65 mL total
- Maximum per session: 200-250 mL
- Transfusion rate in surgical series: 49.75%
- Persistent bleeding (>48h): Surgicel or thrombin-soaked gauze
Monitoring Protocol
- Type and screen before initiating therapy
- Serial hematocrit every 8 hours during active treatment
- Transfusion threshold per institutional protocol
- Document blood loss volume per leech/session
Contraindications
Absolute Contraindications
- Hemophilia or severe coagulopathy
- Hemorrhagic diathesis
- Severe anemia (Hb <8 g/dL)
- Documented allergy to leech SGSry proteins
- Arterial insufficiency at application site
- Hematologic malignancies
- Active sepsis
- Decompensated liver disease
- Patient refusal (consent, antibiotics, or transfusion)
Relative Contraindications
- Concurrent anticoagulant therapy (54.29% in Whitaker series)
- Immunosuppression
- Pregnancy or lactation
- Children under 6 years
- Stable HIV infection
- History of keloid formation at application site
Drug Interactions
| Drug Class | Risk Level | Considerations |
|---|---|---|
| Warfarin | High | Additive anticoagulation; check INR, target lower therapeutic range |
| DOACs (FXa inhibitors) | High | Additive effect; consider timing to trough level |
| Dabigatran | Very High | Mechanistically redundant with hirudin — highest theoretical bleeding risk |
| Heparin | High | Commonly concurrent (54.29%); titrate to aPTT |
| Aspirin/Clopidogrel | Moderate | Additive antiplatelet; do not discontinue if cardiovascular indication |
| NSAIDs | Moderate | Mild additive risk; prefer acetaminophen for analgesia |
| Thrombolytics | Absolute CI | Never use concurrently — extreme hemorrhagic risk |
Waste Disposal
Single-Use Requirement
Medicinal leeches are single-use medical devices. Post-procedure euthanasia is performed by immersion in 70% ethanol. Disposal follows regulated medical waste protocols per OSHA bloodborne pathogen standards and institutional biohazard waste policies.